[ad_1]
AstraZeneca COVID-19 vaccine Is “safe and effective” and should continue to be used, European Medicines Agency Announced today After review Concerns about blood clotting.
But the agency said it cannot rule out a link with two rare blood clotting conditions found in 25 people who received the vaccine. It added that information about vaccines should include warnings. Provided to the doctor And patients. Nine of these people died.
Request the EU’s Pharmacovigilance Risk Assessment Committee (PRAC) to review the safety of AstraZeneca vaccines after review Over 20 European countries-including Germany, France, Italy and Spain- Stop vaccination The following are reports of rare coagulopathy.
After the EMA announcement, Germany, France, Italy and Spain all stated Will resume Use AstraZeneca’s vaccine.
On Thursday, EMA executive director Emer Cooke said at a press conference that compared with the total global population, the committee found that nearly 20 million people worldwide have been vaccinated with the vaccine, thereby reducing the overall incidence of blood clots.
She said: “The committee has reached a clear scientific conclusion.” “This is a safe and effective vaccine.”
However, PRAC chairman Sabine Straus said that experts could not rule out contact with 18 cases. Cerebral Venous Sinus Thrombosis (CVST) and 7 cases Disseminated intravascular coagulation (DIC), you can see a decrease in platelet count. In CVST, clots can prevent blood from draining from the brain, which can lead to bleeding. DIC is a condition in which clots form in many small blood vessels in the body, which can cause serious organ damage.
EMA will continue to investigate these incidents and possible links with the vaccine. But Cook emphasized that the benefits of the AstraZeneca vaccine to protect people from COVID-19 far outweigh any risk of blood clotting, which currently kills thousands of Europeans every week.
She said: “Therefore, the committee recommends raising awareness.”
Some experts speculate that the coagulation event is related to a particular batch of vaccine, but Straus said EMA does not support this theory. She said: “PRAC could not find evidence of quality or batch issues.”
The White House confirmed reports on Thursday that the Biden administration will ship 2.5 million doses of AstraZeneca vaccine to Mexico and 1.5 million doses of AstraZeneca vaccine to Canada. These vaccines will come from existing domestic supplies that are awaiting FDA approval, and these supplies may be released as early as next month after a large-scale trial of the vaccine in the United States ends.
This move followed Required dose Came from Mexico earlier this week. Biden told reporters on Thursday that once domestic vaccination is completed, the United States will discuss the issue of shipping any excess vaccine abroad. Senior FDA official, Peter Marks, testified before Congress on Wednesday that his agency is concerned about exporting excessive amounts of drugs in case the vaccine immunity proves to be short-lived and the Americans need to be boosted by injections.
Others speculate whether AstraZeneca’s vaccine will create more problems in the United States because anti-vaxxers have captured these problems in its launch.
“Does it really have a niche to fill? Will it be trusted enough? Or will it have another headache?” John Moore, a virologist at the Cornell Medical College in New York, told BuzzFeed News earlier this week , He is engaged in vaccine development.
[ad_2]
Source link
